Abstract:Background: Retinitis pigmentosa is an incurable, degenerative retinal condition causing progressive sight loss, significantly affecting patients' quality of life. The Argus II Retinal Prosthesis is a surgically implanted medical device that delivers electrical stimulation to the retina. It is intended to produce a form of artificial vision for blind people with severe-to-profound retinitis pigmentosa by stimulating the remaining viable retinal cells to induce visual perception. This study has been initiated by National Health Service England's Commissioning through Evaluation program and funded through the National Institute of Health Research of the United Kingdom. Objective: The aim of this study was to assess the effect of the Argus II device on patient's daily activities and quality of life. Methods: This protocol is a prospective, single-arm, open-label, mixed methods study on 10 consecutive participants receiving the Argus II device. The patient representatives played an integral role in the design of this study. Eligibility criteria include ultra-low vision in both eyes as a result of end-stage retinitis pigmentosa and a willingness and capacity to complete the postimplantation rehabilitation program. Participants will be interviewed by independent researchers at baseline and 12 months later by using a semistructured, in-depth approach, alongside validated questionnaires (Impact of Vision Impairment-Very Low Vision, 5-level EuroQoL-5 dimensions scale, EuroQoL-visual analog scale, and Hospital Anxiety and Depression Scale) and a bespoke device-related questionnaire, which includes questions about users' experiences with the procedure, the device, and rehabilitation. The effect of the device on patients' functional vision and activities of daily living will be assessed by vision rehabilitation specialists using a set of tests measured on an ordinal scale (eg, ability to locate objects and avoid obstacles). Clinical outcomes include full-field stimulus light threshold, square localization, direction of motion, grating visual acuity, Landolt-C, procedural success, and adverse events. Qualitative and quantitative outcomes will be linked in a single database to enable individual participant measures to be considered in toto, comparing baseline to the final review. Results: This study was approved by the local ethics committee on April 24, 2019 (London-Camberwell St. Giles Research Ethics Committee, reference 19/LO/0429). It has also been approved by the Health Research Authority and Health and Care Research Wales. At the time of protocol writing, Argus II was available for use in the United Kingdom; however, the manufacturer recently withdrew the Argus II device from sale in the United Kingdom. Therefore, the study is not going ahead at this time. Conclusions: The mixed methods approach provides a rich and in-depth assessment of the effect of the device on participants' quality of life. Despite the work not going ahead, the publication of this publicly funded protocol is important for researchers planning similar work. International registered report identifier (irrid): PRR1-10.2196/17436.

Retinitis Pigmentosa Patients' Attitudes Toward Participation in Retinal Prosthesis Trials.

Acupuncture for retinitis pigmentosa: study protocol for a randomised, sham-controlled trial

Preoperative candidate evaluations for retinal prosthesis trials.

Ethical Considerations for Volunteer Recruitment of Visual Prosthesis Trials

Qualitative Interviews to Better Understand the Patient Experience and Evaluate Patient-Reported Outcomes (PRO) in RLBP1 Retinitis Pigmentosa (RLBP1 RP)

Establishing Clinical Trial Endpoints in Selecting Patients for RPGR Retinal Gene Therapy

Evaluation of vision-related quality of life in retinitis pigmentosa patients with low vision

When do patients with retinitis pigmentosa present to ophthalmologists? A multi-centre retrospective study

The attitudes of 1066 patients with cancer towards participation in randomised clinical trials

Systematic Evaluation Of A Targeted Gene Capture Sequencing Panel For Molecular Diagnosis Of Retinitis Pigmentosa

Effects of the Argus II Retinal Prosthesis System on the Quality of Life of Patients With Ultra-Low Vision Due to Retinitis Pigmentosa: Protocol for a Single-Arm, Mixed Methods Study

Transpalpebral electrical stimulation for the treatment of retinitis pigmentosa: study protocol for a series of N-of-1 single-blind, randomized controlled trial

Evaluation of the efficacy of subtenon autologous platelet-rich plasma therapy in patients with retinitis pigmentosa and factors affecting response to the treatment

Driving with retinitis pigmentosa

Retinitis Pigmentosa and Therapeutic Approaches: A Systematic Review

A Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis: A Single-Arm Clinical Trial of Feasibility

Factors influencing willingness to participate in ophthalmic clinical trials and strategies for effective recruitment

Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies

The Concurrent Use of Medical Imaging Modalities and Innovative Treatments to Combat Retinitis Pigmentosa

A multinational survey of potential participant perspectives on ocular gene therapy

Clinical characterization of patients with PRPF31-related retinitis pigmentosa and asymptomatic carriers: a cross-sectional study